Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Biopsy-site-marker in Breast Cancer

NCT: NCT07833566 · RECRUITING

NCT IDNCT07833566
StatusRECRUITING
Start Date2026-07-09
Completion2030-07
SponsorUniversity of Oklahoma (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to explore pro-metastatic changes in breast cancer (BC) associated with the stiffness of biopsy site markers. This study aims to determine whether the stiffness of a biopsy site marker promotes inflammatory changes in breast cancer and to evaluate whether there is a relationship between biopsy site marker stiffness and inflammation.

Frequently Asked Questions

What is Biopsy-site-marker in Breast Cancer?

Biopsy-site-marker in Breast Cancer is a clinical trial registered under NCT07833566. Current status: RECRUITING.

What is the status of NCT07833566?

The current status of NCT07833566 (Biopsy-site-marker in Breast Cancer) is: RECRUITING.

When did Biopsy-site-marker in Breast Cancer start?

Biopsy-site-marker in Breast Cancer started on 2026-07-09.

Related Devices

K161021HydroMARK Breast Biopsy Site MarkerDevicor Medical Products, Inc. K170803HydroMARK Breast Biopsy Site MarkersDevicor Medical Products, Inc. K203097HydroMARK Breast Biopsy Site MarkersDevicor Medical Products, Inc. K210752HydroMARK Breast Biopsy Site MarkerDevicor Medical Products, Inc. K212158HydroMARK Breast Biopsy Site MarkerDevicor Medical Products, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑